NZYM B Stock Overview
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in North America, India, Japan, the Middle East, Africa, South East Asia, Latin America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Novozymes A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.362.80 |
| 52 Week High | kr.400.00 |
| 52 Week Low | kr.274.60 |
| Beta | 0.45 |
| 1 Month Change | 5.74% |
| 3 Month Change | 19.38% |
| 1 Year Change | -0.71% |
| 3 Year Change | 6.33% |
| 5 Year Change | 22.94% |
| Change since IPO | 1,019.75% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 27
An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued
Sep 05Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively
Jul 09Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Jun 24Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
May 02Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively
Apr 07Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Mar 26Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?
Mar 12Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues
Feb 04Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Jan 29Is Novozymes (CPH:NZYM B) Using Too Much Debt?
Dec 23Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture
Dec 05A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)
Oct 14These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well
Sep 13The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence
Aug 29Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Jul 13Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly
Jun 13Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital
May 29Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)
Apr 12Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?
Mar 01Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital
Feb 14Is Novozymes A/S (CPH:NZYM B) Worth kr.537 Based On Its Intrinsic Value?
Jan 01We Think Novozymes (CPH:NZYM B) Can Stay On Top Of Its Debt
Nov 28Many Would Be Envious Of Novozymes' (CPH:NZYM B) Excellent Returns On Capital
Nov 11Is Novozymes A/S (CPH:NZYM B) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 25Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly
Aug 23Returns On Capital Signal Tricky Times Ahead For Novozymes (CPH:NZYM B)
Aug 05Is Novozymes (CPH:NZYM B) Using Too Much Debt?
May 25Novozymes (CPH:NZYM B) May Have Issues Allocating Its Capital
May 07Novozymes A/S (CPH:NZYM B) Pays A kr.5.25 Dividend In Just Three Days
Mar 07Do Its Financials Have Any Role To Play In Driving Novozymes A/S' (CPH:NZYM B) Stock Up Recently?
Mar 04Key Things To Consider Before Buying Novozymes A/S (CPH:NZYM B) For Its Dividend
Feb 17Has Novozymes (CPH:NZYM B) Got What It Takes To Become A Multi-Bagger?
Feb 03Is Novozymes (CPH:NZYM B) Using Too Much Debt?
Jan 20
The Novozymes (CPH:NZYM B) Share Price Is Up 14% And Shareholders Are Holding On
Jan 05Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)
Dec 18Shareholder Returns
| NZYM B | DK Chemicals | DK Market | |
|---|---|---|---|
| 7D | 1.4% | 2.1% | -1.7% |
| 1Y | -0.7% | 3.7% | 16.4% |
Return vs Industry: NZYM B underperformed the Danish Chemicals industry which returned 3.7% over the past year.
Return vs Market: NZYM B underperformed the Danish Market which returned 16.4% over the past year.
Price Volatility
| NZYM B volatility | |
|---|---|
| NZYM B Average Weekly Movement | 3.9% |
| Chemicals Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DK Market | 9.9% |
| 10% least volatile stocks in DK Market | 2.6% |
Stable Share Price: NZYM B is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: NZYM B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 6,820 | Ester Baiget | https://www.novozymes.com |
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in North America, India, Japan, the Middle East, Africa, South East Asia, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Novozymes A/S Fundamentals Summary
| NZYM B fundamental statistics | |
|---|---|
| Market Cap | kr.99.82b |
| Earnings (TTM) | kr.3.21b |
| Revenue (TTM) | kr.17.83b |
31.3x
P/E Ratio5.6x
P/S RatioIs NZYM B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NZYM B income statement (TTM) | |
|---|---|
| Revenue | kr.17.83b |
| Cost of Revenue | kr.8.15b |
| Gross Profit | kr.9.67b |
| Other Expenses | kr.6.46b |
| Earnings | kr.3.21b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 01, 2024
| Earnings per share (EPS) | 11.58 |
| Gross Margin | 54.27% |
| Net Profit Margin | 18.00% |
| Debt/Equity Ratio | 45.5% |
How did NZYM B perform over the long term?
See historical performance and comparison